Evidence map›Paper›PMID 31186755›Full record

ArticleOncology letters2019

Integrating radiosensitive genes improves prediction of radiosensitivity or radioresistance in patients with oesophageal cancer.

Qiuning Zhang, Zhitong Bing, Jinhui Tian, Xiaohu Wang, Ruifeng Liu, Yi Li, Yarong Kong, Yan Yang

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Qiuning ZhangDepartment of Radiation Oncology, The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Zhitong BingEvidence Based Medicine Center, School of Basic Medical Science of Lanzhou University, Lanzhou, Gansu 730050, P.R. China.
Jinhui TianEvidence Based Medicine Center, School of Basic Medical Science of Lanzhou University, Lanzhou, Gansu 730050, P.R. China.
Xiaohu WangDepartment of Radiation Oncology, The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Ruifeng LiuDepartment of Radiation Oncology, The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Yi LiDepartment of Radiation Oncology, The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Yarong KongDepartment of Radiation Oncology, The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Yan YangThe First Clinical Medical College of Lanzhou University, Gansu Provincial Cancer Hospital, Lanzhou, Gansu 730050, P.R. China.
Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oesophageal cancer is a serious disease worldwide. In China, the incidence of esophageal cancer was reported to be ~478,000 in 2015. In the same year, the incidence of esophageal cancer in the United States was ~16,910. Radiotherapy serves as an important tool in the treatment of oesophageal cancer, and although radiation therapy has progressed over time, the prognosis of the majority of patients with oesophageal cancer remains poor. Additionally, the sensitivity of patients with oesophageal cancer to radiotherapy and chemotherapy is not yet clear. Although there are a number of studies on the radiosensitivity of oesophageal cancer cell lines, the vastly different results from different cell lines make them unreliable to use as a guide in clinical practice. Therefore, a common radiosensitive gene signature may provide more reliable results, and using different combinations of common gene signatures to predict the outcome of patients with oesophageal cancer may generate a unique gene signature in oesophageal cancer. In the present study, the radiosensitive index and prognostic index were calculated to predict clinical outcomes. The prognostic index of a 41-gene signature combination is the largest combination of gene signatures used for classifying oesophageal cancer patients into radiosensitive (RS) and radioresistance (RR) groups, to the best of our knowledge, and this gene signature was more effective in patients classified as having Stage III oesophageal cancer. Furthermore, four genes (

Indexed as

clinical outcomeoesophageal cancerprognosisprognostic indexradiosensitive gene signature

Identifiers

PMID31186755
PMCPMC6507505
OpenAlexW2939226113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.